The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis research"
DOI: 10.1016/j.thromres.2022.02.020
Abstract: BACKGROUND Bruton's kinase (Btk) is critical for collagen-triggered platelet signal transduction. The Btk inhibitor ibrutinib has been shown to selectively block platelet adhesion to atherosclerotic plaque material under laminar arterial flow. However, this has not… read more here.
Keywords: inhibitor ibrutinib; plaque material; collagen; ibrutinib ... See more keywords
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006288
Abstract: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in… read more here.
Keywords: ibrutinib; median time; covid; inhibitor ibrutinib ... See more keywords